Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713559 | PMC |
| http://dx.doi.org/10.3324/haematol.2022.281453 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel Treatment Options for Multiple Myeloma.
JCO Oncol Pract
January 2025
Fred Hutchinson Cancer Center, Seattle, WA.
Multiple myeloma (MM), the second most common hematologic malignancy in the United States, is characterized by repeated cycles of remission and relapse, with increasing resistance to treatment after each line of therapy. Despite the virtually incurable nature of MM, recent therapeutic breakthroughs have fundamentally reshaped its treatment landscape. This review explores evolving care paradigms, spanning from newly diagnosed MM to relapsed or refractory disease.
View Article and Find Full Text PDFMulti-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity.
Proc Natl Acad Sci U S A
December 2024
Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD 20850.
Article Synopsis
- Clinical trials for cancer treatments should be based on strong scientific understanding and proven drug effectiveness in relevant disease models.
- This study examines the effects of four small-molecule drugs on lymphoma cell lines, revealing that synergistic combinations effectively induce cell death (apoptosis) in a way that mimics actual drug exposure in patients.
- The findings suggest that in vitro drug screening can help identify effective drug combinations that leverage their synergistic effects to tackle the complexity of human cancers, especially in diverse genetic lymphoma models.
Current status and research directions in acute myeloid leukemia.
Blood Cancer J
September 2024
From the Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
Article Synopsis
- Advances in understanding the molecular pathobiology of acute myeloid leukemia (AML) have led to the development of twelve new targeted therapies approved since 2017, including various inhibitors and antibody-drug conjugates.
- These therapies, such as venetoclax and FLT3 inhibitors, aim to treat specific AML subsets and improve patient outcomes through precision medicine.
- Successful treatment of AML requires specialized expertise, access to diverse therapies, and a strong supportive care system, alongside ongoing research into new treatment options and combinations.
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes.
Clin Lymphoma Myeloma Leuk
September 2024
Division of Hematological Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD. Electronic address:
Higher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents.
View Article and Find Full Text PDFClinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval.
JAMA
May 2024
Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Importance: The US Food and Drug Administration's (FDA) accelerated approval pathway allows approval of investigational drugs treating unmet medical needs based on changes to surrogate measures considered "reasonably likely" to predict clinical benefit. Postapproval clinical trials are then required to confirm whether these drugs offer clinical benefit.
Objective: To determine whether cancer drugs granted accelerated approval ultimately demonstrate clinical benefit and to evaluate the basis of conversion to regular approval.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!